Benzinga | Sep 1, 2020 08:43AM EDT

B. Riley FBR Downgrades Acasti Pharma to Neutral, Lowers Price Target to $0.5

B. Riley FBR analyst Mike Crawford downgrades Acasti Pharma (NASDAQ:ACST) from Buy to Neutral and lowers the price target from $2 to $0.5.